Weekly Digest – February 2025 Weekly Digest – February 2025 12 Feb 2025: U.S. FDA approves Pfizer’s ADCETRIS combination regimen for the treatment of relapsed/refractory diffuse large B-cell lymphoma The FDA approved ADCETRIS (Brentuximab vedotin) for treating adult patients with […]
Weekly Digest – February 2025 Weekly Digest – February 2025 12 Feb 2025: OnCusp Therapeutics receives FDA Fast Track Designation for CUSP06 for the treatment of platinum-resistant ovarian cancer The FDA granted Fast Track Designation to OnCusp Therapeutics’ lead program, […]
Weekly Digest – February 2025 Weekly Digest – February 2025 13 Feb 2025: DAAN Biotherapeutics signs antibody exclusive licensing agreement with LigaChem Biosciences for ADC therapeutic development DAAN Biotherapeutics signed an exclusive licensing deal with LigaChem Biosciences for a tumor-targeting […]
Weekly Digest – February 2025 Weekly Digest – February 2025 13 Feb 2025: IDEAYA announces further Gilead sciences clinical study collaboration evaluating combination of Trodelvy and IDE397 in MTAP-deletion NSCLC The combination targets two complementary mechanisms in MTAP-deletion solid tumors, […]
Weekly Digest – February 2025 Weekly Digest – February 2025 11 February 2025: Ellipses In-Licences first in class novel Immuno-oncology agent with potential as a next generation checkpoint inhibitor Ellipses Pharma will develop GENA-104 (EP0089), a first-in-class monoclonal antibody targeting […]
Weekly Digest – February 2025 Weekly Digest – February 2025 10 Feb 2025: Pfizer and Astellas’ PADCEV (Enfortumab vedotin) plus KEYTRUDA (pembrolizumab) shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer (la/mUC) The EV-302 trial (KEYNOTE-A39) […]
